Kiniksa Pharmaceuticals International, plc
KNSA
Rang in Aktien
#3001
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Aktienkurs
$78.31
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$6.11B
Veränderung (1 Tag)
-2.04%
Veränderung (1 Jahr)
102.67%
Land
GB
Handel Kiniksa Pharmaceuticals International, plc (KNSA)
Kategorie
Healthcare
EPS für Kiniksa Pharmaceuticals International, plc (KNSA)
EPS zum June 2026 TTM: $1.07
Laut den aktuellen Finanzberichten und dem Aktienkurs von Kiniksa Pharmaceuticals International, plc beträgt das aktuelle EPS des Unternehmens (TTM) $1.07. Am Ende des Jahres 2023 betrug das EPS $0.20 ein Rückgang im Vergleich zu dem EPS von 2022, das $2.64 betrug.
EPS-Verlauf von Kiniksa Pharmaceuticals International, plc von 2016 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $1.07 | -278.33% |
| 2024 | $-0.60 | -400.00% |
| 2023 | $0.20 | -92.42% |
| 2022 | $2.64 | -214.78% |
| 2021 | $-2.30 | -11.88% |
| 2020 | $-2.61 | -12.71% |
| 2019 | $-2.99 | -14.33% |
| 2018 | $-3.49 | 74.50% |
| 2017 | $-2.00 | 170.27% |
| 2016 | $-0.74 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $2.41 | 125.23% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.02 | -98.24% |
HK
|
